Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: Modulation by nitric oxide synthase inhibition

Metabolism: Clinical and Experimental

Volumn 45, Issue 9, 1996, Pages 1147-1152

  Cameron, N E ^a   Cotter, M A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; STREPTOZOCIN;

ANIMAL MODEL; ARTICLE; CAPILLARY FLOW; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENDONEURIUM; ENZYME INHIBITION; MALE; NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

EID: 0029759740     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90015-3     Document Type: Article

References (49)

1. Baynes JW: Role of oxidative stress in the development of complications in diabetes. Diabetes 40:405-412, 1991
2. Brownlee M: Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-1843, 1992
3. Sell DR, Monnier VM: End-stage renal disease and diabetes catalyze the formation of a pentose-derived cross-link from aging human collagen. J Clin Invest 85:380-384, 1990
4. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29, 1992
5. Fu M-X, Wells-Knecht KJ, Blackledge JA, et al: Glycation, glycoxidation and cross-linking of collagen by glucose: Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676-683, 1994
6. Soulis-Liparota T, Cooper M, Papazoglou D, et al: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluoresence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
7. Hammes HP, Martin S, Federlin K, et al: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558, 1991
8. Kihara M, Schmelzer JD, Poduslo JF, et al: Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88:6107-6111, 1991
9. Cameron NE, Cotter MA, Dines KC, et al: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolism in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992
10. Low PA, Lagerlund TD, McManis PG: Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int Rev Neurobiol 31:355-438, 1989
11. Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 10:189-224, 1994
12. Tesfaye S, Malik R, Ward JD: Vascular factors in diabetic neuropathy. Diabetologia 37:847-854, 1994
13. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87:432-438, 1991
14. Archibald V, Cotter MA, Keegan A, et al: Contraction and relaxation of aortas from diabetic rats: Effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn Schmiedebergs Arch Pharmacol (in press)
15. Cullum NA, Mahon J, Stringer K, et al: Glycation of rat sciatic tubulin in experimental diabetes mellitus. Diabetologia 34:387-389, 1991
16. Tilton RG, Chang K, Hasan KH, et al: Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
17. Dewhurst M, Stevens EJ, Tomlinson DR: Aminoguanidine attenuates endothelium-dependent relaxation of precontracted aortic rings in control and streptozotocin-induced diabetic rats. Br J Pharmacol 110:174P, 1993 (abstr)
18. Cameron NE, Cotter MA, Dines KC, et al: Pharmacological manipulation of vascular endothelium in non-diabetic and streptozotocin-diabetic rats: Effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 36:516-522, 1993
19. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859, 1994
20. Cameron NE, Cotter MA, Hohman TC: Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 39:172-182, 1996
21. 2 clearance curves used to measure blood flow in rat sciatic nerve. J Physiol 414:35-54, 1989
22. Cameron NE, Cotter MA, Archibald V, et al: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37:449-459, 1994
23. Cameron NE, Cotter MA, Robertson S: Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 30:46-48, 1993
24. Dines KC, Cameron NE, Cotter MA: Comparison of the effects of evening primrose oil and triglycerides containing γ-linolenic acid on nerve conduction and blood flow in diabetic rats. J Pharmacol Exp Ther 273:49-55, 1995
25. Ritchie JM: A note on the mechanism of resistance to anoxia and ischaemia in the pathophysiological mammalian myelinated nerve. J Neurol Neurosurg Psychiatry 48:274-277, 1985
26. Reja A, Tesfaye S, Harris ND, et al: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabetic Med 12:307-309, 1995
27. Yagihashi S, Kamijo M, Baba M, et al: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992
28. Sharma AK, Bajada S, Thomas PK: Influence of streptozotocin-induced diabetes on myelinated nerve fibre maturation and integrity and on body growth in the rat. Acta Neuropathol 53:257-265, 1981
29. Cameron NE, Cotter MA, Harrison J: The effects of diabetes on motor nerve conduction velocity in different branches of the rat sciatic nerve. Exp Neurol 92:757-761, 1986
30. Cameron NE, Cotter MA, Dines KC, et al: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37:651-663, 1994
31. Dewhurst M, Stevens EJ, Karasu C, et al: Effects of aminoguanidine on vasculature and nerves of streptozotocin-diabetic rats, in Hotta N, Greene DA, Ward JD, et al (eds): Diabetic Neuropathy: New Concepts and Insights. Amsterdam, The Netherlands, Elsevier, 1995, pp 109-114
32. Nukuda H, Powell HC, Myers RR: Perineurial window: Demyelination in nonherniated endoneurium with reduced nerve blood flow. J Neuropathol Exp Neurol 51:523-530, 1992
33. Bell MA, Weddell AGM: A descriptive study of the blood vessels of the sciatic nerve in the rat, man and other mammals. Brain 107:871-898, 1984
34. Cotter MA, Love A, Watt MJ, et al: Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38:1285-1294, 1995
35. Kihara M, Zollman PJ, Smithson IL, et al: Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. Am J Physiol 266:E980-E985, 1994
36. Griffiths MJD, Messent M, MacAllister RJ, et al: Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110:963-968, 1993
37. Cameron NE, Cotter MA: Reversal of peripheral nerve conduction and perfusion deficits by the free radical scavenger, BM15.0639, in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 352:685-690, 1995
38. Kihara M, Low PA: Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 132:180-185, 1995
39. Hogan M, Cerami A, Bucala R: Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90:1110-1115, 1992
40. Cameron NE, Cotter MA: Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats. Eur J Clin Invest 25:19-24, 1995
41. Cameron NE, Cotter MA, Low PA: Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am J Physiol 261:E1-E8, 1991
42. Wolff SP: Diabetes mellitus and free radicals. Br Med Bull 49:642-652, 1995
43. Cameron NE, Cotter MA: Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96:1159-1163, 1995
44. Picard S, Parthasarathy S, Fruebis J, et al: Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by the macrophage scavenger receptor. Proc Natl Acad Sci USA 89:6876-6880, 1992
45. Bucala R, Makita Z, Koschinsky T, et al: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438, 1993
46. Morel DW, Chisolm G: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 30:1827-1834, 1989
47. Andrews HE, Brukdorfer KR, Dunn RC, et al: Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 327:237-239, 1987
48. Brown CD, Zhao ZH, De Alvaro F, et al: Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes 42:590-593, 1993
49. Bell MA, Weddell AGM: A morphometric study of intrafascicular vessels of mammalian nerve. Muscle Nerve 7:524-534, 1984